Share

February 28, 2023; 100 (9) Invited Article

Academic Neurology and the COVID-19 Pandemic

Resilience, Hope, and Solutions

Nina F. Schor, Merit E. Cudkowicz, Brenda Banwell
First published December 1, 2022, DOI: https://doi.org/10.1212/WNL.0000000000201571
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
336

Share

Article Information

vol. 100 no. 9 430-436
DOI: 
https://doi.org/10.1212/WNL.0000000000201571
PubMed: 
36456201
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 16, 2022
  • Accepted in final form September 28, 2022
  • First Published December 1, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Nina F. Schor, MD, PhD,
    2. Merit E. Cudkowicz, MD and
    3. Brenda Banwell, MD
  1. Nina F. Schor, MD, PhD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. MedLink Neurology, Pediatric Neurology, Journal of Child Neurology(member of editorial boards of these journals; 2000-present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. Nelson's Textbook of Pediatrics, Elsevier, 2011 and 2013.Swaiman's Pediatric Neurology: Principles and Practice, Elsevier, 2011, 2016.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I was an employee of the National Institute of Neurological Disorders and Stroke at the time of performance of this work. I have been and remain an employee of the NIH (2018-present).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Merit E. Cudkowicz, MD and
    3. Scientific Advisory Boards:

    1. Locust Walk

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Neurotherapeutics editorial boardJAMA Neurology editorial boardAnnals of Neurology Editorial Board

    Patents:

    1. Metabolomics in ALS - patentMIR 155 inhibitor - patent

    Publishing Royalties:

    1. UptoDate MND chapter

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Neurosense, Biogen, Regeneron, Transposon, Locustwalk, Arrowhead, Praxis, Vector, Servier, Eledon, Cytokinetics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grants from UCB, Biohaven, Clene Nanomedicines, Prilenia, Seelos, Calico, Revalesio, all for platform trial

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NINDS - U01 NeuroNEXT

    Research Support, Foundations and Societies:

    1. Muscular dystrophy association, als association, als finding a cure foundation, ALS One

    Stock/Stock Options/Board of Directors Compensation:

    1. Praxis Precision medicine, options, board member

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Brenda Banwell, MD
    4. Scientific Advisory Boards:

    1. Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly,Novartis, UCB, Roche.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Novartis, Roche, UCB

    Editorial Boards:

    1. I serve on the Editorial Board for Neurology. I receive no financial remuneration.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant to Novartis, Roche, Sanofi, and UCB.

    Speakers' Bureaus:

    1. I have spoken at an event supported by the Consortium of MS Centers, the Corpus, and Medscape more than 12 months ago

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of CanadaMultiple Sclerosis Scientific Research FoundationNational Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Institutes of Health (N.F.S.), Bethesda, MD; Massachusetts General Hospital (M.E.C.), Harvard Medical School, Boston, MA; Children's Hospital of Philadelphia (B.B), Perelman School of Medicine, University of Pennsylvania, PA.
  1. Correspondence
    Dr. Banwell banwellb{at}email.chop.edu
View Full Text

Article usage

Article usage: December 2022 to May 2023

AbstractFullPdfSource
Dec 2022436092Highwire
Jan 202394026Highwire
Feb 20238729153Highwire
Mar 20231633172Highwire
Apr 2023710153Highwire
May 202365840Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me